Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant
The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation.
|Study Design:||Observational Model: Defined Population
Time Perspective: Longitudinal
|Official Title:||Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation|
|Study Start Date:||March 2007|
|Estimated Study Completion Date:||March 2007|
Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation.
The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased.
Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant.
We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00456040
|Principal Investigator:||Marc J Semigran, MD||Massachusetts General Hospital|